352514-21-7

Basic information

• Product Name: 2(1H)-Pyridinone,6-(hydroxymethyl)-(9CI)
• Synonyms: 2(1H)-Pyridinone,6-(hydroxymethyl)-(9CI);6-(hydroxymethyl)-2(1H)-Pyridinone;6-(Hydroxymethyl)pyridin-2(1H)-one
• CAS NO: 352514-21-7
• Molecular Formula: C6H7NO2
• Molecular Weight: 125.12528
• Product Categories: PYRIDINE
• Mol File: 352514-21-7.mol

Chemical Properties

• Boiling Point: 431.9±27.0 °C(Predicted)
• Appearance: /
• Density: 1.225±0.06 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 10.92±0.10(Predicted)
• CAS DataBase Reference: 2(1H)-Pyridinone,6-(hydroxymethyl)-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2(1H)-Pyridinone,6-(hydroxymethyl)-(9CI)(352514-21-7)
• EPA Substance Registry System: 2(1H)-Pyridinone,6-(hydroxymethyl)-(9CI)(352514-21-7)

Safety Data

• Hazardous Substances Data: 352514-21-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2(1H)-Pyridinone,6-(hydroxymethyl)-(9CI) is used as a building block in organic synthesis for the preparation of various pharmaceuticals. Its unique structural features make it a promising candidate for the development of new drugs and therapeutic agents.
Used in Agrochemical Industry:
In the agrochemical industry, 2(1H)-Pyridinone,6-(hydroxymethyl)-(9CI) is utilized as a key intermediate in the synthesis of agrochemicals, contributing to the development of effective and environmentally friendly pest control solutions.
Used in Fine Chemicals Industry:
2(1H)-Pyridinone,6-(hydroxymethyl)-(9CI) serves as a valuable intermediate in the production of other complex organic molecules, particularly in the fine chemicals industry. Its versatility allows for its use in the synthesis of a wide range of specialty chemicals with diverse applications.
Used in Medicinal Chemistry and Drug Discovery:
Due to its unique structural features, 2(1H)-Pyridinone,6-(hydroxymethyl)-(9CI) has potential applications in medicinal chemistry and drug discovery. It can be employed as a starting material or intermediate in the development of novel therapeutic agents with improved efficacy and selectivity.
Overall, 2(1H)-Pyridinone,6-(hydroxymethyl)-(9CI) is a promising chemical compound with a wide range of applications across various industries, making it an essential component in the development of innovative products and solutions.

Upstream product

• 19621-92-2 6-Hydroxypicolinic acid 
• 110-71-4 1,2-dimethoxyethane 
• 19621-92-2 2-oxo-1,2-dihydropyridine-6-carboxylic acid 

Downstream Products

• 358751-77-6 6-hydroxypicolinaldehyde 

Relevant articles and documents

ADENOSINE RECEPTOR BINDING COMPOUNDS

The present invention relates to pharmaceutical compounds and compositions of Formula (I) and methods of treatment using the compounds and compositions, especially for the treatment and/or prevention of a proliferation disorder, such as cancer. Compounds of Formula (I) as further described herein are shown modulators of the adenosine A2A receptor and exhibit antiproliferative activity. Accordingly, these compounds are useful to treat proliferative disorders such as cancer, and other adenosine receptor-related conditions including an inflammatory disease, renal disease, diabetes, vascular disease, lung disease, or an autoimmune disease.

METAL CHELATING COMPOUNDS FOR USE IN TREATING DISEASES

The present invention relates to heterocyclic compounds for use in the treatment of diseases. In particular, the invention relates to heterocyclic compounds for use in the treatment of neurodegenerative diseases, such as Parkinson's or Alzheimer's disease, and methods of making and using the same. The heterocycle compounds contain at least one electronegative atom and comprise a hydroxyl group or substituted hydroxyl group at the 1-position and the carbon at the 2-position being a carbonyl group.

BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF GLYTL MEDIATED DISORDERS

The present invention relates to benzoxazinone derivatives, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in treating disorders mediated by GlyT1, including neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder.

Gonadotropin releasing hormone receptor antagonists

The present invention relates to Gonadotropin Releasing Hormone (“GnRH”) (also known as Leutinizing Hormone Releasing Hormone) receptor antagonists.

Novel pleuromutilin derivatives

Pleuromutilin compounds of the formula (A) and (B) are of use in anti-bacterial therapy.